Impact of age on coronary artery plaque progression and clinical outcome: A PARADIGM substudy.
Adult
Age Factors
Aged
Computed Tomography Angiography
Coronary Artery Disease
/ diagnostic imaging
Disease Progression
Female
Heart Disease Risk Factors
Humans
Male
Middle Aged
Plaque, Atherosclerotic
Predictive Value of Tests
Prognosis
Prospective Studies
Registries
Risk Assessment
Vascular Calcification
/ diagnostic imaging
Aging
Computed tomography
Coronary artery disease
Disease progression
atherosclerotic plaque
Journal
Journal of cardiovascular computed tomography
ISSN: 1876-861X
Titre abrégé: J Cardiovasc Comput Tomogr
Pays: United States
ID NLM: 101308347
Informations de publication
Date de publication:
Historique:
received:
15
06
2020
revised:
26
08
2020
accepted:
28
09
2020
pubmed:
10
10
2020
medline:
15
7
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
The association of age with coronary plaque dynamics is not well characterized by coronary computed tomography angiography (CCTA). From a multinational registry of patients who underwent serial CCTA, 1153 subjects (61 ± 5 years old, 61.1% male) were analyzed. Annualized volume changes of total, fibrous, fibrofatty, necrotic core, and dense calcification plaque components of the whole heart were compared by age quartile groups. Clinical events, a composite of all-cause death, acute coronary syndrome, and any revascularization after 30 days of the initial CCTA, were also analyzed. Random forest analysis was used to define the relative importance of age on plaque progression. With a 3.3-years' median interval between the two CCTA, the median annual volume changes of total plaque in each age quartile group was 7.8, 10.5, 10.8, and 12.1 mm The rate of whole-heart plaque progression and dense calcification increases depending on age. Age is a significant factor in plaque growth, the importance of which is comparable to other traditional risk factors. URL: http://www.clinicaltrials.gov. Unique identifiers: NCT02803411.
Sections du résumé
BACKGROUND
BACKGROUND
The association of age with coronary plaque dynamics is not well characterized by coronary computed tomography angiography (CCTA).
METHODS
METHODS
From a multinational registry of patients who underwent serial CCTA, 1153 subjects (61 ± 5 years old, 61.1% male) were analyzed. Annualized volume changes of total, fibrous, fibrofatty, necrotic core, and dense calcification plaque components of the whole heart were compared by age quartile groups. Clinical events, a composite of all-cause death, acute coronary syndrome, and any revascularization after 30 days of the initial CCTA, were also analyzed. Random forest analysis was used to define the relative importance of age on plaque progression.
RESULTS
RESULTS
With a 3.3-years' median interval between the two CCTA, the median annual volume changes of total plaque in each age quartile group was 7.8, 10.5, 10.8, and 12.1 mm
CONCLUSIONS
CONCLUSIONS
The rate of whole-heart plaque progression and dense calcification increases depending on age. Age is a significant factor in plaque growth, the importance of which is comparable to other traditional risk factors.
CLINICAL TRIAL REGISTRATION
BACKGROUND
URL: http://www.clinicaltrials.gov. Unique identifiers: NCT02803411.
Identifiants
pubmed: 33032975
pii: S1934-5925(20)30448-2
doi: 10.1016/j.jcct.2020.09.009
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02803411']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
232-239Informations de copyright
Copyright © 2020 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Min receives funding from the Dalio Foundation, National Institutes of Health, and GE Healthcare and serves on the scientific advisory board of Arineta and GE Healthcare, and has an equity interest in Clearly. Dr. Samady serves on the scientific advisory board of Philips, has equity interest in Covanos Inc., and has a research grant from Medtronic. The remaining authors have no relevant disclosures.